We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ABBV34 market cap is 102.01B. The company's latest EPS is USD 2.7544 and P/E is 62.21.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 12.24B | 14.03B | 13.93B | 14.3B | 12.31B |
| Operating Income | 2.77B | 4.51B | 2.28B | 3.2B | 2.8B |
| Net Income | 239M | 2.02B | 1.78B | 822M | 1.37B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 34.16B | 45.8B | 56.2B | 58.05B | 54.5B |
| Operating Income | 12.98B | 11.36B | 17.92B | 18.12B | 12.76B |
| Net Income | 7.88B | 4.62B | 11.54B | 11.84B | 4.86B |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 134.54B | 135.37B | 136.22B | 134.71B | 148.87B |
| Total Liabilities | 121.24B | 122.47B | 124.09B | 124.31B | 140.83B |
| Total Equity | 13.3B | 12.9B | 12.13B | 10.4B | 8.05B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 89.12B | 150.57B | 146.53B | 138.81B | 134.71B |
| Total Liabilities | 97.29B | 137.47B | 131.09B | 121.52B | 124.31B |
| Total Equity | -8.17B | 13.1B | 15.44B | 17.29B | 10.4B |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 4.19B | 10.51B | 18.09B | 22.84B | 4.04B |
| Investing | -499M | -840M | -1.21B | -2.01B | -9.59B |
| Financing | -6.19B | -10.11B | -12.77B | -17.22B | 10.82B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 13.32B | 17.59B | 22.78B | 24.94B | 22.84B |
| Investing | 596M | -37.56B | -2.34B | -623M | -2.01B |
| Financing | 18.71B | -11.5B | -19.04B | -24.8B | -17.22B |
| Market Cap | 102.01B |
| Price to Earnings Ratio | 62.21 |
| Price to Sales Ratio | 5.55 |
| Price to Cash Ratio | 23.61 |
| Price to Book Ratio | 29.1 |
| Dividend Yield | 2.51% |
| Shares Outstanding | 1.77B |
| Average Volume (1 week) | 2.56k |
| Average Volume (1 Month) | 789 |
| 52 Week Change | 40.93% |
| 52 Week High | 59.34 |
| 52 Week Low | 39.68 |
| Spread (Intraday) | 0.36 (0.62%) |
| Company Name | Abbvie Inc |
| Address |
1521 concord pike suite 201 wilmington, delaware 19803 |
| Website | https://www.abbvie.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
